Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Standard Biotools (LAB) Accumulated Depreciation & Amortization (2016 - 2025)

Standard Biotools (LAB) has disclosed Accumulated Depreciation & Amortization for 15 consecutive years, with $46.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 1110.47% to $46.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $46.7 million, a 1110.47% increase, with the full-year FY2024 number at $12.3 million, up 261.76% from a year prior.
  • Accumulated Depreciation & Amortization was $46.7 million for Q3 2025 at Standard Biotools, down from $70.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $70.1 million in Q1 2025 to a low of $2.8 million in Q4 2022.
  • A 5-year average of $14.9 million and a median of $4.8 million in 2021 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 86.17% in 2023, then soared 1249.08% in 2025.
  • Standard Biotools' Accumulated Depreciation & Amortization stood at $3.2 million in 2021, then fell by 13.02% to $2.8 million in 2022, then rose by 21.43% to $3.4 million in 2023, then skyrocketed by 261.76% to $12.3 million in 2024, then skyrocketed by 279.67% to $46.7 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Accumulated Depreciation & Amortization are $46.7 million (Q3 2025), $70.1 million (Q1 2025), and $12.3 million (Q4 2024).